Renovia Inc. recently raised $42 million toward the establishment of a new pipeline of drugs as well as therapeutic products made to target pelvic floor disorders that affect more than 200 million women across the world. Situated in Boston, the revolutionary medtech company is seeking the support of various donors when it comes to treating disorders including urinary incontinence. In the fundraiser, $10 million was raised and channelled toward the project. $32 million was raised from a round of Series B Funding that was chaired by Perceptive Advisors alongside Ascension Ventures. The two firms are situated in New York as well as Missouri in that order. Longwood Fund was part of the project as well.
Regarding the contribution, Marc Beer, CEO of Renovia Inc stated that he was elated by this investor’s support. He added that the donation would be forwarded toward the development of drugs that would occur through the combination of the company’s proprietary form factors as well as sensor technologies. In the long-run, the idea would offer constructive data-driven treatment dockets aimed at cutting down the healthcare costs for treating pelvic floor disorders.
Renovia Inc. created Leva for pelvic floor strengthening customized to help individuals suffering from different forms of pelvic floor disorders. The healthcare system has sensor technology that is designed to allow the user to identify the position of the pelvic floor muscles during exercise. The FDA has approved the device. It has also been cleared for training patient’s weak pelvic floor muscles particularly when treating stress incontinence in addition to the moderate urge incontinence.
Marc Beer established Renovia Inc. in 2016. He is the chairman of the company and has been serving in the sector of biotechnology for over two decades. Beer is prominent for working with various companies in the same industry. They include ViaCell in which he served as the CEO and founding partner. With his guidance, the company specialized in developing as well as preserving stem cells harvested from the umbilical cord. In 2007, Beer served at PerkinElmer before acquiring it.
Additionally, he worked at Erytech Pharma which is a biopharmaceutical firm. Marc Beer also served as a member of the board of directors. Moreover, Marc Beer has worked at Genzyme where he was the VP of Global Marketing. He assisted the company to launch various brands made for treating rare diseases in the world.
Renovia Inc. was established to create and commercialize products for better diagnosis as well as treatment to improve the conditions of millions of women who suffer from pelvic floor disorders. The technology makes it possible for patients to gain access to treatment through accurate visualization of various pelvic floor movements during training. The process is also monitored to establish the results. Learn more: https://renoviainc.com/leadership/